



## pNPP Substrate, Tablet

Cat. No.	Format	Size
0201-01	Tablet	50 x 5 mg

### Overview

<b>Technical Name</b>	<i>para</i> -Nitrophenyl phosphate
<b>Reaction Product</b>	Produces a soluble, yellow end product upon reaction with alkaline phosphatase (AP) that is measurable between 405 nm and 410 nm

### Applications

ELISA <sup>1-15</sup>

### Product Use

- Substrate buffer - To 400 mL of distilled water, add 24.5 mg MgCl<sub>2</sub>·6H<sub>2</sub>O and 48 mL diethanolamine. Adjust pH to 9.8 with 5 N HCl and make up to 500 mL with distilled water. Store at room temperature.
- Substrate solution - Just prior to use, dissolve pNPP tablet in substrate buffer to a final substrate concentration of 1.0 mg/mL (5 mL substrate buffer per 5 mg tablet).
- Reaction may be stopped with 3 N NaOH

### Handling and Storage

- Recommended storage is at -20°C.
- Protect from light. Reagent is stable for the period shown on the label if stored as directed.

### References

1. Hunt JS, Jadhav L, Chu W, Geraghty DE, Ober C. Soluble HLA-G circulates in maternal blood during pregnancy. *Am J Obstet Gynecol.* 2000;183:682-8. (ELISA)
2. Paisansinsup T, Vallejo AN, Luthra H, David CS. HLA-DR modulates autoantibody repertoire, but not mortality, in a humanized mouse model of systemic lupus erythematosus. *J Immunol.* 2001;167:4083-90. (ELISA)
3. Matza D, Lantner F, Bogoch Y, Flaishon L, Hershkoviz R, Shachar I. Invariant chain induces B cell maturation in a process that is independent of its chaperonic activity. *Proc Natl Acad Sci USA.* 2002;99:3018-23. (ELISA)
4. Haas KM, Toapanta FR, Oliver JA, Poe JC, Weis JH, Karp DR, et al. Cutting edge: C3d functions as a molecular adjuvant in the absence of CD21/35 expression. *J Immunol.* 2004;172:5833-7. (ELISA)
5. Yu PW, Tabuchi RS, Kato RM, Astrakhan A, Humblet-Baron S, Kipp K, et al. Sustained correction of B-cell development and function in a murine model of X-linked agammaglobulinemia (XLA) using retroviral-mediated gene transfer. *Blood.* 2004;104:1281-90. (ELISA)
6. Dzhagalov I, Giguère V, He Y. Lymphocyte development and function in the absence of retinoic acid-related orphan receptor  $\alpha$ . *J Immunol.* 2004;173:2952-9. (ELISA)
7. Kobayashi M, Yasui N, Ishimaru N, Arakaki R, Hayashi Y. Development of autoimmune arthritis with aging via bystander T cell activation in the mouse model of Sjögren's syndrome. *Arthritis Rheum.* 2004;50:3974-84. (ELISA)
8. Lee Y, Haas KM, Gor DO, Ding X, Karp DR, Greenspan NS, et al. Complement component C3d-antigen complexes can either augment or inhibit B lymphocyte activation and humoral immunity in mice depending on the degree of CD21/CD19 complex engagement. *J Immunol.* 2005;175:8011-23. (ELISA)
9. Al-Sayyed B, Piperdi S, Yuan X, Li A, Besra GS, Jacobs WR Jr, et al. Monoclonal antibodies to Mycobacterium tuberculosis CDC 1551 reveal subcellular localization of MPT51. *Tuberculosis (Edinb).* 2007;87:489-97. (ELISA)
10. Leech MD, Chung C, Culshaw A, Anderton SM. Peptide-based immunotherapy of experimental autoimmune encephalomyelitis without anaphylaxis. *Eur J Immunol.* 2007;37:3576-81. (ELISA)
11. Kigerl KA, Gensel JC, Ankeny DP, Alexander JK, Donnelly DJ, Popovich PJ. Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord. *J Neurosci.* 2009;29:13435-44. (ELISA)
12. Kolla RV, Chintalapati S, Sabet M, Santelli E, Liddington RC, David M, et al. Complement C3d conjugation to anthrax protective antigen promotes a rapid, sustained, and protective antibody response. *PLoS One.* 2007;10:e1044. (ELISA)
13. Kobold S, Tams S, Luetkens T, Cao Y, Sezer O, Bartels BM, et al. Patients with multiple myeloma develop SOX2-specific autoantibodies after allogeneic stem cell transplantation. *Clin Dev Immunol.* 2011;2011:302145. (ELISA)
14. Luckey D, Bastakoty D, Mangalam AK. Role of HLA class II genes in susceptibility and resistance to multiple sclerosis: studies using HLA transgenic mice. *J Autoimmun.* 2011;37:122-8. (ELISA)
15. Atanackovic D, Reinhard H, Meyer S, Spöck S, Grob T, Luetkens T, et al. The trifunctional antibody catumaxomab amplifies and shapes tumor-specific immunity when applied to gastric cancer patients in the adjuvant setting. *Hum Vaccin Immunother.* 2013;9:2533-42. (ELISA)

**For Research Use Only. Not for Diagnostic or Therapeutic Use.**

TB0201  
16-Sep-15

**Corporate Offices:** 160 Oxmoor Blvd • Birmingham, AL 35209 • USA **Mailing Address:** P.O. Box 26221 • Birmingham, AL 35260 • USA

**Tel:** 205.945.1774 • U.S. and Canada: 800.722.2255 • **Fax:** 205.945.8768

**Email:** [info@southernbiotech.com](mailto:info@southernbiotech.com) • **Website:** [www.southernbiotech.com](http://www.southernbiotech.com)